📇 Rhumatologue · ANGERS CEDEX 9 · (49) · Hospitalier

MME MARIE BRIET

Pourquoi vous devez consulter ce praticien

5 raisons identifiées

Plateau technique de référence
Centre hospitalier universitaire (CHU) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
38 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (1 thèse dirigée)
Expérience confirmée
19 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
121.5 rhumatos / 100 000 hab. — département bien doté

Rhumatologue

📍 ANGERS CEDEX 9 (49)HospitalierRPPS 10001610889

Expérience confirmée

19ans d'exercice (thèse 2007)

📊 Reconnaissance scientifique : 30/100📝 179 articles publiés🇫🇷 Publications académiques françaises (8)🎓 1 thèse dirigée

✨ Génération du profil synthétique IA en cours…

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Chemsex/slamsex-related intoxications: A case report involving gamma-hydroxybutyrate (GHB) and 3-methylmethcathinone (3-MMC) and a review of the literature

Forensic science international · 2021

📚 39 citations🎯 RCR 5.11Top 8% NIH

In utero exposure to Azathioprine in autoimmune disease. Where do we stand?

Autoimmunity reviews · 2020

📚 30 citations🎯 RCR 2.35Top 22% NIH🔓 Open Access📄 PDF gratuit ↗

Drug-induced vitiligo: a case/non-case study in Vigibase(®) , the WHO pharmacovigilance database

Fundamental & clinical pharmacology · 2020

📚 22 citations🎯 RCR 1.47

Lire l'abstract Crossref ↓

AbstractVitiligo is a common depigmenting disorder ensuing the loss of epidermal melanocytes. It is a multifactorial disease with immunological, genetic and environmental factors including drug exposure. The purpose of the study was to investigate the drugs and therapeutic subclasses associated with vitiligo occurrence reported in VigiBase®, the WHO pharmacovigilance database. A case/non‐case study was carried out by defining cases as vitiligo reports and non‐cases as all other reports. The reporting odds ratio (ROR) was calculated for the ‘suspected’ drugs and drug classes according to ATC level 4. During the study period, 741 cases of vitiligo were registered. Mean age was 49 ± 20 years. The disproportionality analysis showed an association between vitiligo and pembrolizumab (ROR 116.9, 95% Confidence Interval (CI) 94.8, 144.3), nivolumab (ROR 22.6, 95% CI 15.8, 32.4), ipilimumab (ROR 41.7, 95% CI 25.0, 69.7), imiquimod (ROR 152.8, 95% CI 103.0, 226.7), adalimumab (ROR 3.8, 95% CI 2.5,5.8), infliximab (ROR 2.6, 95% CI 1.65, 4.01), alemtuzumab (ROR 27.8, 95% CI 17.6, 43.9), and ustekinumab (ROR 9.3, 95% CI 5.6, 15.6). Concerning the pharmacological classes ATC level 4, a significant association was found with monoclonal antibodies, interferons, selective immunosuppressants, TNF‐alpha inhibitors, interleukin inhibitors, and topical antivirals. This study confirmed the expected associations between vitiligo and immune checkpoint inhibitors and strengthened the emerging signal about the association between vitiligo and imiquimod, TNF‐alpha inhibitors and interferons. New signals were shown with selective immunosuppressants including alemtuzumab and interleukin inhibitors.

Cookies & analyse de trafic

MME MARIE BRIET

Pourquoi vous devez consulter ce praticien

Thèses universitaires

Direction de thèses

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (38) — classées par pathologie

Transversal23

Revue générale8

Case report / série7

Pharmacovigilance3

Pédiatrie2

Gériatrie1

Partager cette fiche